Research association - 24/07/2024

SPI-MP: pioneer in personalised medical technology

Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

For her ground-breaking scientific studies in the field of synthetic biology, the 2024 Alfried Krupp Advancement Award is to go to Prof. Dr Kerstin Göpfrich. The award, endowed with one million euros in funding, is granted annually by the Alfried Krupp von Bohlen und Halbach Foundation to young academics holding their first professorship in the natural and engineering sciences.

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU).

HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.

Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.

A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

Expert interview - 28/06/2023

Money isn't all that is needed – knowledge and networking can also help start-ups move forward

Dr. Rolf Neuhaus is one of the driving forces behind PALATINA Business Angels Rhein-Neckar e.V., a business angels association in the Rhine-Neckar metropolitan region. In an interview with BIOPRO, Neuhaus describes the association’s activities and explains where there is still catching up to be done in terms of start-up support in Baden-Württemberg.

Proteins have characteristic amino acid sequences, the analysis of which is fundamental for research and medicine. These can be decoded; however, so-called protein sequencing is expensive and time-consuming. A large-scale research project led by Prof. Dr. Jan Behrends from the Institute of Physiology at the University of Freiburg now aims to establish a new technology for protein sequencing using nanopores, which will be rapid and cost-effective.

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

With insects to the circular economy - 30/11/2022

InBiRa: Insect biorefinery turns food leftovers into new products

Insect larvae can convert food leftovers and waste into secondary raw materials for technical products and cosmetics. Researchers are looking to establish an insect biorefinery for this purpose at the Fraunhofer IGB in Stuttgart. The InBiRa project is financed with a total of 3.8 million euros in EU and Baden-Württemberg state funding.

The Carl Zeiss Foundation is funding the "DELIVER - Data-driven Engineering of Sustainable Living Materials" project at the University of Freiburg in its "CZS Wildcard" program. In the project, scientists from the Freiburg Clusters of Excellence CIBSS and livMatS will develop sustainable wood-based materials whose properties can be precisely controlled.

The Carl Zeiss Foundation is funding the "DELIVER - Data-driven Engineering of Sustainable Living Materials" project at the University of Freiburg in its "CZS Wildcard" program. In the project, scientists from the Freiburg Clusters of Excellence CIBSS and livMatS will develop sustainable wood-based materials whose properties can be precisely controlled.

More animal welfare and better animal health, more climate protection and less environmental impact: Researchers at the University of Hohenheim in Stuttgart are pursuing these goals with a new approach: They are exploring the interplay between farm animals and the millions of microorganisms in the animals’ digestive tracts. The federal and state governments are supporting the university with the construction of a unique research center for around…

Project BW2Pro - 29/08/2022

Biowaste to Products: biorefinery transforms biowaste into new products

In 2020, Germany’s population collected over 5 million tonnes of biowaste. Most of this was composted, and some was fermented into biogas. Scientists in Baden-Württemberg think there's room for more. Within the project ‘Biowaste to Products’ (BW2Pro) they want to transform biowaste into new products in a biorefinery. The idea is to produce biodegradable plant pots, mulch material, fertilisers, enzymes and biobased plastics in addition to…

Press release - 22/06/2022

Concluding conference of the ARDIA-Net Interreg project

On May 11, the concluding conference of the ARDIA-Net Interreg project took place with 18 in-person attendees in Milan and 18 online participants. The programme for the half-day event included presentations and two panels on the project results as well as discussions on further cross-regional cooperation.